Found: 74
Select item for more details and to access through your institution.
Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01155-y
- By:
- Publication type:
- Article
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. N.PAG, doi. 10.1186/s13045-020-00948-5
- By:
- Publication type:
- Article
Nutrition support use and clinical outcomes in patients with multiple myeloma undergoing autologous stem cell transplant.
- Published in:
- Supportive Care in Cancer, 2022, v. 30, n. 11, p. 9341, doi. 10.1007/s00520-022-07358-y
- By:
- Publication type:
- Article
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR).
- Published in:
- British Journal of Haematology, 2024, v. 205, n. 4, p. 1337, doi. 10.1111/bjh.19624
- By:
- Publication type:
- Article
A sequential cohort study evaluating single‐agent KappaMab and KappaMab combined with lenalidomide and low‐dose dexamethasone in relapsed and/or refractory kappa light chain‐restricted multiple myeloma (AMaRC 01‐16).
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 4, p. 801, doi. 10.1111/bjh.18955
- By:
- Publication type:
- Article
The second revision of the International Staging System (R2‐ISS) stratifies progression‐free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 2, p. e17, doi. 10.1111/bjh.18536
- By:
- Publication type:
- Article
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 5, p. 830, doi. 10.1111/bjh.18324
- By:
- Publication type:
- Article
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 4, p. 784, doi. 10.1111/bjh.17541
- By:
- Publication type:
- Article
Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 2, p. 219, doi. 10.1111/bjh.14829
- By:
- Publication type:
- Article
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
- Published in:
- British Journal of Haematology, 2017, v. 177, n. 3, p. 441, doi. 10.1111/bjh.14562
- By:
- Publication type:
- Article
Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. E83, doi. 10.1002/ajh.26434
- By:
- Publication type:
- Article
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 10, p. E383, doi. 10.1002/ajh.26282
- By:
- Publication type:
- Article
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 9, p. 1120, doi. 10.1002/ajh.26261
- By:
- Publication type:
- Article
Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 6, p. 708, doi. 10.1002/ajh.26172
- By:
- Publication type:
- Article
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma.
- Published in:
- Annals of Hematology, 2020, v. 99, n. 12, p. 2837, doi. 10.1007/s00277-020-04021-6
- By:
- Publication type:
- Article
Failure of eculizumab to correct paroxysmal cold hemoglobinuria.
- Published in:
- 2011
- By:
- Publication type:
- Letter
Real‐world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry.
- Published in:
- Internal Medicine Journal, 2024, v. 54, n. 5, p. 773, doi. 10.1111/imj.16277
- By:
- Publication type:
- Article
Australia and New Zealand consensus position statement: use of COVID‐19 therapeutics in patients with haematological malignancies.
- Published in:
- Internal Medicine Journal, 2024, v. 54, n. 2, p. 328, doi. 10.1111/imj.16303
- By:
- Publication type:
- Article
Peripheral blood stem cell mobilisation following bortezomib, lenalidomide and dexamethasone induction for multiple myeloma: a real‐world single‐centre experience.
- Published in:
- Internal Medicine Journal, 2024, v. 54, n. 1, p. 108, doi. 10.1111/imj.16170
- By:
- Publication type:
- Article
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia.
- Published in:
- Internal Medicine Journal, 2023, v. 53, n. 5, p. 819, doi. 10.1111/imj.16049
- By:
- Publication type:
- Article
Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
- Published in:
- Internal Medicine Journal, 2023, v. 53, n. 4, p. 599, doi. 10.1111/imj.15980
- By:
- Publication type:
- Article
Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia.
- Published in:
- Internal Medicine Journal, 2021, v. 51, n. 10, p. 1707, doi. 10.1111/imj.15457
- By:
- Publication type:
- Article
COVID‐19 vaccination in haematology patients: an Australian and New Zealand consensus position statement.
- Published in:
- Internal Medicine Journal, 2021, v. 51, n. 5, p. 763, doi. 10.1111/imj.15247
- By:
- Publication type:
- Article
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic.
- Published in:
- Internal Medicine Journal, 2020, v. 50, n. 6, p. 667, doi. 10.1111/imj.14859
- By:
- Publication type:
- Article
Considerations for pre‐transfusion immunohaematology testing in patients receiving the anti‐CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
- Published in:
- Internal Medicine Journal, 2018, v. 48, n. 2, p. 210, doi. 10.1111/imj.13707
- By:
- Publication type:
- Article
Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.
- Published in:
- Internal Medicine Journal, 2017, v. 47, n. 8, p. 938, doi. 10.1111/imj.13502
- By:
- Publication type:
- Article
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
- Published in:
- Internal Medicine Journal, 2017, v. 47, n. 1, p. 35, doi. 10.1111/imj.13311
- By:
- Publication type:
- Article
Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview.
- Published in:
- Cancers, 2020, v. 12, n. 11, p. 3488, doi. 10.3390/cancers12113488
- By:
- Publication type:
- Article
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant‐ineligible patients with myeloma who are treated with bortezomib‐based induction.
- Published in:
- European Journal of Haematology, 2021, v. 107, n. 4, p. 497, doi. 10.1111/ejh.13677
- By:
- Publication type:
- Article
Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-49776-9
- By:
- Publication type:
- Article
Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells.
- Published in:
- Frontiers in Immunology, 2020, v. 11, p. N.PAG, doi. 10.3389/fimmu.2020.02153
- By:
- Publication type:
- Article
Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 6, p. 358, doi. 10.1016/j.clml.2024.02.004
- By:
- Publication type:
- Article
Listening to What Matters Most: Consumer Endorsed Patient Reported Outcome Measures (PROMs) for Use in Multiple Myeloma Clinical Trials: A Descriptive Exploratory Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 7, p. 505, doi. 10.1016/j.clml.2023.03.008
- By:
- Publication type:
- Article
Corrigendum.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 545, doi. 10.1016/j.clml.2022.03.011
- By:
- Publication type:
- Article
Corrigendum to P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) Pages S152-S153]
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 6, p. 424, doi. 10.1016/j.clml.2022.03.009
- By:
- Publication type:
- Article
P-204: Carfilzomib, Dexamethasone, and Daratumumab (KdD) vs Kd: subgroup analysis of the CANDOR study by prior autologous stem cell transplantation, Lenalidomide exposure, or Lenalidomide refractory disease.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S150, doi. 10.1016/S2152-2650(21)02331-4
- By:
- Publication type:
- Article
P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S150, doi. 10.1016/S2152-2650(21)02330-2
- By:
- Publication type:
- Article
P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S109, doi. 10.1016/S2152-2650(21)02264-3
- By:
- Publication type:
- Article
P-116: The impact of SLiM criteria in myeloma in a real-life population: clinical characteristics, treatment and outcome from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S98, doi. 10.1016/S2152-2650(21)02243-6
- By:
- Publication type:
- Article
P-074: Assessing the immune microenvironment with multiplex immunofluorescence histochemistry demonstrates proximity of cytotoxic T-cells to plasma cells in patients with newly diagnosed multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S79, doi. 10.1016/S2152-2650(21)02208-4
- By:
- Publication type:
- Article
OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S1, doi. 10.1016/S2152-2650(21)02075-9
- By:
- Publication type:
- Article
MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S424, doi. 10.1016/S2152-2650(21)01950-9
- By:
- Publication type:
- Article
Poster: MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S252, doi. 10.1016/S2152-2650(21)01581-0
- By:
- Publication type:
- Article
Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 7, p. 444, doi. 10.1016/j.clml.2021.02.002
- By:
- Publication type:
- Article
The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR).
- Published in:
- 2021
- By:
- Publication type:
- journal article
Perspectives in the Rapidly Evolving Treatment Landscape of Multiple Myeloma: Expert Review of New Data Presentations from ASH 2019.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Patient Reported Outcome Measures in multiple myeloma: real-time rePorTing to improve care (My-PROMPT) - a pilot randomised controlled trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e340, doi. 10.1016/j.clml.2019.09.561
- By:
- Publication type:
- Article
Carfilzomib, Thalidomide and Dexamethasone (KTd) is safe and effective in RRMM: interim analysis of the single arm, multicentre phase II ALLG MM018/AMN002 study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e274, doi. 10.1016/j.clml.2019.09.452
- By:
- Publication type:
- Article